Vilya has secured USD 71 million in a Series A funding round led by founding investor ARCH Venture Partners, with participation from NVentures, Menlo Ventures, Madrona, Lifeforce Capital, and Altitude Life Science Ventures. Concurrent with the funding, Menlo Ventures' Partner Greg Yap has joined the board of directors.
The funds raised are intended to strengthen Vilya's proprietary GenAI-based computational drug design platform, increasing the variety of macrocycles the firm can synthesize and develop. The company also plans to advance its designed macrocycles to clinical-stage candidates.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.